The global women’s health diagnostics market accounted for USD 148.80 billion in 2023 and is expected to reach at USD 324.66 billion by 2034 with a CAGR of 7.35% during the forecast period 2024-2034. Rising incidence of infectious diseases such as hepatitis & urinary tract infections among women, increase in prevalence of chronic conditions, growing demand for early disease detection, surge in advancements in technology, rising approvals from regulatory bodies, and surge in the introduction of diagnostic tests tailored specifically for women's health are some of the key factors boosting the market growth.
Surge in the introduction of diagnostic tests tailored specifically for women's health is predicted to boost the market growth during the forecast period. The assessment and management of conditions and illnesses that can impact the physical and mental well-being of women are encompassed within women's health diagnostics. This field covers a range of specialties and areas of focus, including gynecological disorders, breast and ovarian cancer, contraception, sexually transmitted infections (STIs), menopause, hormone therapy, pregnancy and childbirth, osteoporosis, and benign conditions that may affect female bodily functions. For instance, in December 2023, Arva Health, a startup dedicated to women's healthcare utilizing data-driven insights, has launched home fertility tests designed for women. As stated in a press release, these tests enable women to monitor and track their hormone levels, empowering them to make informed decisions regarding their reproductive health.
By type, diagnostic tests was the highest revenue-grossing segment in the global women’s health diagnostics market in 2023 owing to the increasing use of kits & reagents for conducting tests such as cancer biopsies, prenatal genetic testing, & infectious disease testing, rise in the occurrence of various health issues among women such as cancer & infertility, growing awareness regarding tests related to women's health, and high demand for point-of-care diagnostic testing. Additionally, diagnostic devices is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of chronic conditions among women, rise in technological innovations within diagnostic devices, and surge in the introduction of advanced systems. For instance, in June 2022, During Euroanaesthesis 2022, Mindray introduced the TEX20 Series, an exceptional Point of Care ultrasound system that has revolutionized the assessment of patient status in challenging conditions, particularly in critical care and emergency medicine settings.
By application, infectious diseases was the highest revenue-grossing segment in the global women’s health diagnostics market in 2023 owing to the prevalence of infectious diseases such as sexually transmitted diseases (STDs) is on the rise, and increase in approvals by regulatory authorities. For instance, in March 2023, Visby Medical's sexual health test, utilizing self-collected vaginal swabs, has received approval from the U.S. FDA. This second-generation PCR diagnostic is capable of detecting sexually transmitted infections, including trichomoniasis, chlamydia, and gonorrhea. Additionally, cancer is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of breast cancer, and growing demand for early disease detection.
By end-user, hospitals was the highest revenue-grossing segment in the global women’s health diagnostics market in 2023 owing to the rising preference for diagnostic center by women for detecting cancer, infectious diseases, osteoporosis, as well as conducting pregnancy & fertility tests and growing trend of introducing new and innovative diagnostic tests. For instance, in February 2023, Genetic Technologies Limited, a prominent international figure in genomics-based testing for health, well-being, and critical illnesses, introduced a pioneering comprehensive risk assessment test. This groundbreaking test aims to assess the likelihood of a woman developing breast and/or ovarian cancer due to either an inherited genetic mutation or the more prevalent familial or sporadic forms of cancer. Additionally, homecare is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend among market players to invest in the commercialization of portable & point-of-care devices and growing recognition of home diagnostic devices.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing acceptance of highly advanced products, rising introduction of new products, expanding government support, and heightened collaboration among industry players. For instance, in May 2023, SOPHiA GENETICS revealed that Natural State Laboratories, a cutting-edge molecular laboratory situated in Little Rock, Arkansas, has opted for SOPHiA GENETICS technology to enhance its cancer testing and research capacities. Natural State Laboratories is set to initiate the utilization of SOPHiA DDM to introduce internal testing for genetic predispositions to cancer. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the enhancement of healthcare infrastructure, heightened recognition of women's health issues, greater involvement of women in professional endeavors, and uptick in the introduction of new diagnostic tests. For instance, in June 2022, Mylab Discovery Solutions, a well-known diagnostics firm based in India, ventured into the realm of women's healthcare with the release of its home pregnancy test kit, PregaScreen. The company intends to broaden its product portfolio by unveiling a variety of creative and cost-effective solutions tailored to address the diverse needs of women spanning different age demographics.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Surge in the introduction of diagnostic tests tailored specifically for women's health is predicted to boost the market growth during the forecast period. The assessment and management of conditions and illnesses that can impact the physical and mental well-being of women are encompassed within women's health diagnostics. This field covers a range of specialties and areas of focus, including gynecological disorders, breast and ovarian cancer, contraception, sexually transmitted infections (STIs), menopause, hormone therapy, pregnancy and childbirth, osteoporosis, and benign conditions that may affect female bodily functions. For instance, in December 2023, Arva Health, a startup dedicated to women's healthcare utilizing data-driven insights, has launched home fertility tests designed for women. As stated in a press release, these tests enable women to monitor and track their hormone levels, empowering them to make informed decisions regarding their reproductive health.
By type, diagnostic tests was the highest revenue-grossing segment in the global women’s health diagnostics market in 2023 owing to the increasing use of kits & reagents for conducting tests such as cancer biopsies, prenatal genetic testing, & infectious disease testing, rise in the occurrence of various health issues among women such as cancer & infertility, growing awareness regarding tests related to women's health, and high demand for point-of-care diagnostic testing. Additionally, diagnostic devices is predicted to grow at the fastest CAGR during the forecast period owing to the growing incidence of chronic conditions among women, rise in technological innovations within diagnostic devices, and surge in the introduction of advanced systems. For instance, in June 2022, During Euroanaesthesis 2022, Mindray introduced the TEX20 Series, an exceptional Point of Care ultrasound system that has revolutionized the assessment of patient status in challenging conditions, particularly in critical care and emergency medicine settings.
By application, infectious diseases was the highest revenue-grossing segment in the global women’s health diagnostics market in 2023 owing to the prevalence of infectious diseases such as sexually transmitted diseases (STDs) is on the rise, and increase in approvals by regulatory authorities. For instance, in March 2023, Visby Medical's sexual health test, utilizing self-collected vaginal swabs, has received approval from the U.S. FDA. This second-generation PCR diagnostic is capable of detecting sexually transmitted infections, including trichomoniasis, chlamydia, and gonorrhea. Additionally, cancer is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of breast cancer, and growing demand for early disease detection.
By end-user, hospitals was the highest revenue-grossing segment in the global women’s health diagnostics market in 2023 owing to the rising preference for diagnostic center by women for detecting cancer, infectious diseases, osteoporosis, as well as conducting pregnancy & fertility tests and growing trend of introducing new and innovative diagnostic tests. For instance, in February 2023, Genetic Technologies Limited, a prominent international figure in genomics-based testing for health, well-being, and critical illnesses, introduced a pioneering comprehensive risk assessment test. This groundbreaking test aims to assess the likelihood of a woman developing breast and/or ovarian cancer due to either an inherited genetic mutation or the more prevalent familial or sporadic forms of cancer. Additionally, homecare is predicted to grow at the fastest CAGR during the forecast period owing to the rising trend among market players to invest in the commercialization of portable & point-of-care devices and growing recognition of home diagnostic devices.
North America region is anticipated for the highest revenue share during the forecast period owing to the increasing acceptance of highly advanced products, rising introduction of new products, expanding government support, and heightened collaboration among industry players. For instance, in May 2023, SOPHiA GENETICS revealed that Natural State Laboratories, a cutting-edge molecular laboratory situated in Little Rock, Arkansas, has opted for SOPHiA GENETICS technology to enhance its cancer testing and research capacities. Natural State Laboratories is set to initiate the utilization of SOPHiA DDM to introduce internal testing for genetic predispositions to cancer. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increase in the enhancement of healthcare infrastructure, heightened recognition of women's health issues, greater involvement of women in professional endeavors, and uptick in the introduction of new diagnostic tests. For instance, in June 2022, Mylab Discovery Solutions, a well-known diagnostics firm based in India, ventured into the realm of women's healthcare with the release of its home pregnancy test kit, PregaScreen. The company intends to broaden its product portfolio by unveiling a variety of creative and cost-effective solutions tailored to address the diverse needs of women spanning different age demographics.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Application, and End-user
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of Top 10+ Major Market Players
Segmentation: Women’s Health Diagnostics Market Report 2023 - 2034
Women’s Health Diagnostics Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)
- Diagnostic Devices
- Imaging and Monitoring System
- Biopsy Devices
- Diagnostic Tests
- Pregnancy Testing and Ovulation Testing
- PAP Smear (PAP) and HPV Test
- Breast Cancer Testing
- Other Diagnostic Tests
Women’s Health Diagnostics Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Cancer
- Prenatal
- Osteoporosis
- Infectious Disease
- Pregnancy & Fertility
Women’s Health Diagnostics Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Home Care
- Hospitals
- Laboratory
- Others
Women’s Health Diagnostics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Women’s Health Diagnostics Market: Type Estimates & Trend Analysis
8. Women’s Health Diagnostics Market: Application Estimates & Trend Analysis
9. Women’s Health Diagnostics Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Women’s Health Diagnostics Market
12. Europe Global Women’s Health Diagnostics Market
13. Asia Pacific Global Women’s Health Diagnostics Market
14. Latin America Global Women’s Health Diagnostics Market
15. MEA Global Women’s Health Diagnostics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Koninklijke Philips N.V.
- F. Hoffmann-la Roche Ltd.
- Quest Diagnostics Incorporated
- Ge Healthcare
- Abbott Laboratories
- Hologic Inc.
- Becton
- Dickinson
- and Company
- Siemens Aktiengesellschaft
